Stay updated on Nivolumab with 5-azacytidine in Childhood AML Clinical Trial

Sign up to get notified when there's something new on the Nivolumab with 5-azacytidine in Childhood AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab with 5-azacytidine in Childhood AML Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Revision tag updated from v3.4.2 to v3.4.3. No visible changes to study details, eligibility criteria, or locations.
    Difference
    0.1%
    Check dated 2026-03-06T18:31:17.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.1 to v3.4.2; this is a minor platform update with no changes to study information. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-13T13:20:41.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    - Revision: v3.4.1 added; Revision: v3.4.0 removed.
    Difference
    0.1%
    Check dated 2026-02-06T09:22:12.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    Added UI text for glossary toggles (Show glossary, Hide glossary) and new policy/version labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0); removed the prior wording (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).
    Difference
    0.3%
    Check dated 2026-01-22T17:57:39.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Page revision updated from v3.3.3 to v3.3.4.
    Difference
    0.1%
    Check dated 2026-01-14T03:27:53.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Locations were consolidated into a single 'Locations' section, replacing the previous separate state entries (California, Georgia, Maryland, New York, North Carolina, Ohio, Tennessee, Texas, Utah, Washington). The HHS Vulnerability Disclosure link was removed and the revision label updated to v3.3.3.
    Difference
    1%
    Check dated 2025-12-23T20:42:57.000Z thumbnail image

Stay in the know with updates to Nivolumab with 5-azacytidine in Childhood AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab with 5-azacytidine in Childhood AML Clinical Trial page.